In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/16201
PMID: 32585891
DOI: 10.3390/md18060326
ISSN: 1660-3397
Date issued
2020Journal title
Marine Drugs
Type of content
Journal Article
DeCS
animales | estructura molecular | Pseudomonas aeruginosa | alcaloides | Agelas | Porifera | biofilms | antibacterianos | Acinetobacter baumannii | Klebsiella pneumoniaeMeSH
Biofilms | Porifera | Acinetobacter baumannii | Molecular Structure | Anti-Bacterial Agents | Animals | Alkaloids | Pseudomonas aeruginosa | Agelas | Klebsiella pneumoniaeAbstract
The pyrrole-imidazoles, a group of alkaloids commonly found in marine sponges belonging to the genus Agelas, display a wide range of biological activities. Herein, we report the first chemical study of the secondary metabolites of the sponge A. dilatata from the coastal area of the Yucatan Peninsula (Mexico). In this study, we isolated eight known alkaloids from an organic extract of the sponge. We used NMR and MS analysis and comparison with existing databases to characterize the alkaloids: ageliferin (1), bromoageliferin (2), dibromoageliferin (3), sceptrin (4), nakamuric acid (5), 4-bromo-1H-pyrrole-2-carboxylic acid (6), 4,5-dibromopyrrole-2-carboxylic acid (7) and 3,7-dimethylisoguanine (8). We also evaluated, for the first time, the activity of these alkaloids against the most problematic multidrug-resistant (MDR) pathogens, i.e., the Gram-negative bacteria Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Bromoageliferin (2) displayed significant activity against P. aeruginosa. Comparison of the antibacterial activity of ageliferins 1-3 (of similar structure) against P. aeruginosa revealed some relationship between structure and activity. Furthermore, in in vitro assays, 2 inhibited growth and biofilm production in clinical strains of P. aeruginosa. Moreover, 2 increased the survival time in an in vivo Galleria mellonella model of infection. The findings confirm bromoageliferin (2) as a potential lead for designing new antibacterial drugs.